Key result
Routine perioperative metoprolol in non-cardiac surgery reduced myocardial infarction (4.2% vs 5.7%) but increased mortality (3.1% vs 2.3%) and stroke (1.0% vs 0.5%) compared to placebo.
Why the study?
Does routine perioperative metoprolol reduce cardiac risk in patients undergoing non-cardiac surgery?
Population
8,351 patients undergoing non-cardiac surgery (POISE study population)
Comparison
Metoprolol 200 mg daily in a slow-release… vs Placebo
Design
Editorial
Follow-up
perioperative
Authors
Loading...
Routine high-dose perioperative beta-blockade in intermediate-risk patients undergoing non-cardiac surgery is potentially harmful, increasing mortality and stroke despite reducing myocardial infarction.
Does routine perioperative metoprolol reduce cardiac risk in patients undergoing non-cardiac surgery?
Absolute Event Rate: 4.2% vs 5.7%
Routine high-dose perioperative beta-blockade in intermediate-risk patients undergoing non-cardiac surgery is potentially harmful, increasing mortality and stroke despite reducing myocardial infarction.
Oksanen et al. (2009) conducted an editorial in non-cardiac surgery (n=8,351). Metoprolol vs. Placebo was evaluated on perioperative myocardial infarction. Routine perioperative metoprolol in non-cardiac surgery reduced myocardial infarction (4.2% vs 5.7%) but increased mortality (3.1% vs 2.3%) and stroke (1.0% vs 0.5%) compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: